Download Shao-Cong Sun, Ph.D.

Society of Chinese Bioscientists in America
Name of Member________________________________
2015 ELECTION BALLOT
OFFICE
NOMINEES
1. PRESIDENT: (VOTE FOR 1)
(Jan. 1, 2018 - Dec. 31, 2019)
2. SECRETARY: (VOTE FOR 1)
(Jan. 1, 2018 - Dec. 31, 2019)
3. TREASURER: (VOTE FOR 1)
(Jan. 1, 2018 - Dec. 31, 2019)
4. COUNCILOR: (VOTE FOR 2)
(Jan. 1, 2016 - Dec. 31, 2019)
5. NOMINATION: (VOTE FOR 6)
(Jan. 1, 2016 - Dec. 31, 2017)
6. MEMBERSHIP: (VOTE FOR 6)
(Jan. 1, 2016 - Dec. 31, 2017)
VOTE (√)
Pu Paul Liu (NHGRI, Nat. Institutes of Health)
_____
Lin Mei (Georgia Regents university)
_____
Jianming Xu (Baylor College of Medicine)
_____
Bing Gao (NIAAA, Nat. Institutes of Health)
_____
Fen Wang (Texas A&M Health Sci. Center)
_____
Pan Zheng (Children’s National Medical Center)
_____
Keji Zhao (NHLBI, Nat. Institutes of Health)
_____
Mien-Chie Hung (MD Anderson Cancer Center)
_____
Yimin Zou (University of California, San Diego)
_____
Min Han (Univ. of Colorado, Boulder)
_____
Paul J. Chiao (University of Texas, Houston)
_____
Yingzi Yang (Harvard University)
_____
Huilin Zhou (University of California, San Diego)
_____
Qi-Jing Li (Duke University)
_____
Wanjun Chen (NIDCR, Nat. Institutes of Health)
_____
Julian J.-L. Chen (Arizona State University)
_____
Xin Wei Wang (NCI, Nat. Institutes of Health)
_____
Yi Li (Baylor College of Medicine)
_____
Xuhang Li (Johns Hopkins University)
_____
Wei Gu (Columbia University)
_____
Zhibin Chen (University of Miami)
_____
Yingming Zhao (University of Chicago)
_____
Deyu Fang (Northwestern University)
_____
Yixian Zheng (Carnegie Institution of Science)
_____
Yue Xiong (University of North Carolina)
_____
You must type or sign your name on this ballot for your votes to be counted.
All votes will be kept strictly confidential.
Please return your signed BALLOT by June 1, 2015 via e-mail attachment to the
SCBA Co-Executive Director, Chris Lau: [email protected] and
The SCBA Treasurer, Hui Zheng: [email protected]
Candidates for President 1. PRESIDENT: (VOTE FOR 1) Pu Paul Liu (NHGRI, Nat. Institutes of Health) _____ (Jan. 1, 2018 -­‐ Dec. 31, 2019) Lin Mei (Georgia Regents university) _____ Pu Paul Liu, MD, Ph.D.
Current Positions:
Deputy Scientific Director
Senior Investigator (tenured)
National Human Genome Research Institute
(NHGRI), NIH
Education and training:
MD, Capital Medical University, Beijing, China, 1982
Ph.D., Genetics, University of Texas, GSBS at Houston, 1991
Postdoctoral fellow, HHMI and University of Michigan, 1992-1993
Previous Positions:
1993 – 1995
1995 - 2001
2006
Senior Staff Fellow, National Center for Human Genome Research, NIH
Tenure-Track Investigator, National Center for Human Genome Research, NIH
Acting Chief, Genetics and Molecular Biology Branch, NHGRI
Research Interests:
My laboratory investigates the molecular mechanisms of leukemia, a collection of diseases that
strikes approximately 43,000 Americans each year. We focus our attention on two transcription factors,
RUNX1 and CBF, which play major roles in human leukemia pathogenesis. These two proteins also play
critical roles at multiple stages of hematopoiesis. Understanding their roles during hematopoiesis will
enhance our understanding of their involvement in leukemogenesis, as well as their roles in related
hematologic diseases such as familial platelet disorder, in which RUNX1 is mutated. Significantly, I cloned
the breakpoints of chromosome 16 inversion, a common chromosome abnormality in human acute myeloid
leukemia, and identified the molecular consequence of the inversion as the generation of a fusion gene,
CBFB-MYH11. My lab has been the leader for the study of this fusion gene in the past 20 years. We use
genetic and genomic approaches, as well as mouse and zebrafish models, for our research. We carry out
chemical library screens and we recently started using human iPS cells for our investigations as well. Our
long-term goal is to translate our findings to improved clinical practices including better diagnosis and
treatment of leukemia and other related hematologic diseases.
Previous services to SCBA:
2009
President, Baltimore-Washington Chapter, 2009
2011
Organizing Committee, 13th SCBA International Symposium, Guangzhou, China
2011Editorial Board Member, Cell & Bioscience
2014-2017
Council Member
Selected Honors and Awards, and non-SCBA services:
1994 – 1997
Leukemia Society of America Special Fellow
1999
Election to the American Society for Clinical Investigation
2002
John H. Blaffer Lecture, MD Anderson Cancer Center, Houston, TX
2002, 2007, 2009
NIH Merit Award
2004
Election to Association of American Physicians
2007
NIH Asian and Pacific Islander Organization Scientific Achievement Award
2010
NIH Director’s Award
2008-2013
Member, American Cancer Society LIB peer review committee
Member, Scientific Committee on Myeloid Biology, American Society of
2011-2017
Hematology
2006Chair, NHGRI Promotion & Tenure Committee
2008Senior Advisor to Deputy Director for Intramural Research, NIH
2011Chair, NHGIR IC Standing Committee
2013-2015
Co-Chair, NIH Earl Stadtman Investigator Search Executive Committee
2014-2017
Editorial Board Member, Blood
1
Page 1 of 1
Lin Mei
Current Positions:
Professor and Chair, Department of Neuroscience and Regenerative
Medicine, Medical College of Georgia, Georgia Regents University
Education:
Diploma of Medicine, 1982, Jiangxi Medical College (now Nanchang
University), China
MS (Neuropharmacology), 1985, Institute of Pharmacology &
Toxicology, Beijing, China.
PhD (Pharmacology and Toxicology), 1989, University of Arizona.
Postdoctoral Fellow, Department of Neuroscience, Johns Hopkins
University, School of Medicine.
Appointments:
1994-1999, Assistant Professor, Department of Pharmacology, University of Virginia School of
Medicine, Charlottesville, Virginia
1999-2002, Assistant Professor; 2002-2004 Associate Professor, Neurobiology, Pathology, and
Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham,
Alabama
2004-present, Professor of Neurology; 2009-2014, Director of Institute of Molecular Medicine and
Genetics; 2014-present, Professor and Chair (Inaugural), Department of Neuroscience and
Regenerative Medicine, Medical College of Georgia, Georgia Regents University, Augusta,
Georgia
Research Interest:
My laboratory is interested in synapse formation and function. Our research contributes to a better
understanding of pathophysiological mechanisms of muscular dystrophy and brain disorders
including schizophrenia.
Past Service to SCBA:
Life-time member (since 2004; member since 1994).
2009, Co-Chair, Program Committee of 2009 SCBA International Symposium, Taipei.
2011, Session Chair, 13th SCBA International Symposium, Guangzhou, China.
2014 – present, Associate Editor, Cell & Bioscience.
Selected Honors:
1987, Honorary Citizen of Tucson, the City of Tucson, Arizona; 2004, Outstanding Young Investigator
Award (Type B), National Natural Science Foundation, China; 2004, Georgia Research Alliance
Eminent Scholar in Neuroscience; 2005, Chung Kong (Chang Jiang) Scholar, Li Ka Shing
Foundation of Hong Kong and Ministry of Education, China; 2008, Mathilde Solowey Lecture Award
in Neurosciences, Foundation for Advanced Education in Sciences at NIH; 2008, Distinguished
Investigator, National Alliance for Research on Schizophrenia and Depression (NARSAD); 2009,
Alberta Heritage Foundation for Medical Research Visiting Lecturer; 2011, Thousand Talents Scholar
(Type B), Central Coordination Committee on the Recruitment of Talents Project, China; 2014,
Fellow, American Association for the Advancement of Science (AAAS)
-1-
Candidates for Secretary 2. SECRETARY: (VOTE FOR 1) Jianming Xu (Baylor College of Medicine) _____ (Jan. 1, 2018 -­‐ Dec. 31, 2019) Bing Gao (NIAAA, Nat. Institutes of Health) _____ JIANMING XU, Ph.D.
Current Positions:
Professor with Tenure
Department of Molecular and Cellular Biology and Dan
Duncan Cancer Center
Baylor College of Medicine
Education and Training:
B.S., China West Normal University, China 1982
M.S., Beijing Normal University, China 1985
Ph.D., Clarkson University, NY, USA 1994
Postdoctoral fellow, IBT, Texas A&M University
Health Science Center, TX, USA 1993-1994
Postdoctoral fellow, Baylor College of Medicine, TX,
USA 1994-1997
Previous Positions:
1997-1999
Instructor, Department of Molecular and Cellular Biology (MCB), Baylor College of
Medicine (BCM)
1999-2005
Assistant Professor, Department of MCB, BCM
2005-2010
Associate Professor, Department of MCB, BCM
2010-present Professor, Department of MCB and Dan Duncan Cancer Center, BCM
Research Interest:
My laboratory has a longstanding interest in steroid hormone regulated gene expression and steroid
hormone promoted cancers including breast, prostate and endometrial cancers. We were the first to use
genetically manipulated mouse models to define the genetic roles of the initially identified several nuclear
receptor coregulators including SRC-1, SRC-3 (AIB1) and NCOA6 (AIB3) in development, steroidregulated organ function and steroid-promoted cancers. We continue investigating the molecular
mechanisms responsible for transcriptional coregulators to promote or inhibit steroid-promoted
carcinogenesis and trying to identify molecular inhibitors of these coregulators for inhibiting cancer cell
growth and metastasis.
Past Services to SCBA:
• A member of SCBA Nomination Committee, 1/2012 – 12/2013.
• Life-time member of SCBA 2004
• The Treasure of SCBA TX Chapter, 2005 – 2006
• The President Elect of SCBA TX Chapter, 2009 – 2010
• The President of SCBA TX Chapter, 2010 – 2011
• As one of the four committee members, Co-organized the SCBA-TX Annual Symposium, 4/29/2006,
Houston, TX, ~200 attendees.
• As one of the four committee members, Co-organized the 2009 SCBA-TX Annual Symposium,
4/25/2010, Houston, TX, ~200 attendees.
• As one of the four committee members, Co-organized the 2010 SCBA-TX Annual Symposium,
5/1/2010, Houston, TX, ~200 attendees.
• The Chairperson of the Organization Committee, organized the Texas-Sichuan International
Biomedical Research Symposium on behalf of SCBA-TX, Chengdu 2010. Chengdu, China, 10/2410/27/2010. (There were 45 speakers with 26 from USA and about 250 audiences. The scientific
program includes three plenary sections, and a total of 8 concurrent sessions with 2 at a time. I was
•
•
•
•
•
•
responsible for setting up the entire program and inviting all the speakers. I also represented SCBATX to give a speech in the Opening Ceremony in addition to a research lecture, and to coordinate all
the meeting business with our local host, Luzhou Medical College.)
The Chairman of the Organization Committee, SCBA-TX 2011 Annual Meeting, Houston, TX, 4-232011 at Baylor College of Medicine. Chaired the entire one day meeting: a morning symposium with
six speakers; an election and financial report section; a trainee presentation section with six separate
groups; a keynote speaker section; and an award ceremony and closing section. About a total of 200
attendees.
Member of the Organizing Committee, 2011 SCBA International Symposium. Served as the Session
Co-chair for: Breast Cancer, Stem Cells and Metastasis. Guangzhou, China, Aug. 25-29, 2011.
Member of the Organizing Committee, The Second Biennial International Symposium of the SCBATX Chapter: Jiangsu-Texas Biomedical Symposium. Frontier on Cancer and Other Human DiseasesFrom Mechanisms to Bedside. Sept. 14-18, 2012, Nanjing, China. About 400 people attended this
meeting.
Co-Chair with Dr. Sophia Tsai to run the session of “Prostate Cancer Perspectives”, The 14th SCBA
International Symposium, Xi-An, China, July 18-22, 2013.
Co-Chair with Dr. Yi Li to run the session of “Breast Cancer Development”, The 14th SCBA
International Symposium, Xi-An, China, July 18-22, 2013.
Member of the Organizing Committee: China-US Biomedical Symposium, co-organized by the
Society of Chinese Bioscientists in America Texas Chapter and the Fourth Affiliated Hospital of
Hebei Medical University. Shi Jia Zhuang, China, Oct. 18-20, 2014
Selected Achievements, Honors and Awards:
• 140 publications related to the research fields of growth factor receptors, nuclear hormone
receptors, transcriptional coregulators, embryonic development, reproductive biology, breast
cancer and prostate cancer.
• Mentored 10 graduate students for PhD and trained 33 postdoctoral fellows.
• 82 invited research lectures or presentations.
• Journal editorial boards: Journal of Biological Chemistry, 7/2010 –9/2015; International
Journal of Biological Sciences, 4/2006–present; The Open Breast Cancer Journal, 2/2009present; Acta Academiae Medicinae Militaris Tertiae, 2008–present; Cell & Bioscience, 2011–
present.
• Professor Alexander Yeu-Ming Wang Memorial Research Award from SCBA-TX, 4/1998.
• Quest Diagnostics Young Investigator Award from the Endocrine Society, 6/1998.
• Endocrine Society Travel Grant Award, 6/2001.
• Breast Cancer Research Career Award from the US Department of Defense, 4/2000.
• Mellon Foundation Young Investigator Research Award, 4/2002.
• The Cancer Research Award, 1/2005, The Charlotte Geyer Foundation.
• The Research Scholar Award, 1/2005, The American Cancer Society.
• 2008 Research Medal Award, Department of MCB, BCM.
• The Era of Hope 2005 – Department of Defense Breast Cancer Research Program Meeting
Travel Award, 6/8/2005.
BIN GAO, MD., PhD
Current Position:
Chief, Laboratory of Liver Diseases
NIAAA, NIH
Education and training:
MD.: Wannan Medical College, China 1986
PhD: Norman Bethune Medical University, 1991
Postdoctoral Fellow: 1991-1992: NIH; 1992-1995: Medical College of Virginia
Previous Positions:
1995-2000: Assistant Professor, Department of Pharmacology/Toxicology, Medical College of Virginia
2000-2005: Tenure track investigator, Chief, Section on Liver Biology, NIAAA, NIH
2005-2009: Senior Investigator, Chief, Section on Liver Biology, NIAAA, NIH
2009-present: Senior Investigator, Chief, Laboratory of Liver Diseases, NIAAA, NIH
Research Interest:
Immunological aspects and molecular pathogenesis of liver diseases
Hepatic inflammation and immunity in liver diseases
Novel therapeutic targets of alcoholic and nonalcoholic liver diseases
Past service to SCBA:
2010-2011: President, SCBA DC-Baltimore chapter
2011: Organizer and Chair: SCBA local chapter and NIAAA joint symposium on Digestive Diseases, NIH
2011: session organizer and chair: Stem cell symposium at the Annual CBA meeting, MD
2011: session organizer and chair, The 13th SCBA International Conference, Guangzhou
2015-16: SCBA nomination committee
2015: session chair, the first SCBA DC-Baltimore chapter symposium
Selected Honors and Awards:
1991: Forgarty International Visiting Fellow Award, NIAAA, NIH
2000: International Society for Biomedical Research on Alcoholism (ISBRA) Junior Investigator Award
2002: Elected to the American Society for Clinical Investigation (ASCI) Member
2008: Named as the member of Senior Biomedical Research Service (SBRS) by NIH director
2010: NIH Asian & Pacific Islander American Organization (APAO) award
Candidates for Treasurer 3. TREASURER: (VOTE FOR 1) Fen Wang (Texas A&M Health Sci. Center) (Jan. 1, 2018 -­‐ Dec. 31, 2019) Pan Zheng (Children’s National Medical Center) _____ _____ FEN WANG, Ph.D.
Current Positions:
Professor and Director, Center for Cancer and Stem Cell Biology, Institute of
Biosciences and Technology, Texas A&M Health Science Center
Education and Training:
B.S., Microbiology, Xiamen University, 1982, Xiamen, China
M. S., Cell Biology, Xiamen University, 1985, Xiamen, China
Ph. D., Biochemistry/Cell Biology, Clarkson University, 1994 Potsdam, NY
Postdoctoral Fellow, Texas A&M University, Houston, TX 1994-1996
Previous Positions:
1996-1999
Assistant Research Scientist, Institute of Biosciences and
Technology, Texas A&M Health Science Center, Houston,
Texas
2000-2006
Assistant Professor, Institute of Biosciences and Technology,
Texas A&M Health Science Center, Houston, Texas
2006-2010
Associate Professor with tenure, Institute of Biosciences and Technology, Texas A&M
Health Science Center, Houston, Texas
2010-Present Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Research Interests:
The laboratory focuses on understanding the molecular basis of cell signaling, and how aberrant cell
signaling leads to birth defects and causes cancers. Using in vitro cell culture systems and in vivo
mouse models, we study how the fibroblast growth factor (FGF) activates its receptor (FGFR) tyrosine
kinase, and how the activated FGFR transmits the signals to downstream targets and regulates
proliferation, differentiation, homeostasis, and function of the cells, as well as in organogenesis and
development, including prostate and cardiovascular system development. The laboratory also employs
molecular biology, cell biology, and mouse genetic technologies to study how aberrant FGF signals
promote tumor initiation, progression, and metastasis. In addition, how environmental factors
contribute to tumorigenesis and congenital birth defects by modulating FGF signal intensity and
specificity is also under the scope of our research interests.
Past Service to SCBA:
•
Life-time member of SCBA 2003
•
The Treasure of SCBA TX Chapter, 2003 – 2004
•
The Secretary of SCBA TX Chapter, 2004 – 2005
•
The President Elect of SCBA TX Chapter, 2006 – 2007
•
The President of SCBA TX Chapter, 2007 – 2008
• Organizing Committee, Annual Symposium, Society of Chinese Bioscientists in America,
Texas Chapter, 2006
• Organizing Committee, Annual Symposium, Society of Chinese Bioscientists in America,
Texas Chapter, 2007
Selected Honors and Awards, and non-SCBA Service
•
2015President, Xiamen University America Alumni Association,
•
2014President, Dr. Deyao Wang and Wenzheng Wang Scholarship Foundation,
Pan Zheng, MD, PhD
Current Position:
Senior Investigator and McKnew Professor of Cancer Biology
Center for Cancer and Immunology Research
Children’s National Medical Center, Washington, DC
Education and training:
MD, Peking Union Medical College, Beijing, China, 1979 – 1987.
Resident, Internal Medicine, PUMC Hospital, Beijing, China, 1987 – 1989.
PhD, Immunobiology, Yale University, New Haven, CT, 1994.
Resident, Pathology, New York University, NY, 1994 - 1998.
Previous Positions:
1998 – 2003: Assistant Professor, Dept of Pathology, The Ohio State University School of Medicine.
2003 – 2006: Associate Professor, Dept of Pathology, The Ohio State University School of Medicine.
2006 – 2011: Associate Professor, Dept of Surgery and Pathology, University of Michigan School of
Medicine.
2011 – 2013: Professor, Dept of Surgery and Pathology, University of Michigan School of Medicine.
Research Interest:
My research interests are tumor immunology, cancer biology and signal transduction in hematopoietic
stem cells. One of our major efforts is in study TSC-mTOR signaling in rejuvenation of hematopoietic
stem cells (HSC) and immunity. Using genetically modified mice with conditionally deletion of
hematopoietic lineage cells, we demonstrated that mTOR inhibition is critical to maintain hematopoietic
stem cell quiescence. Activation of mTOR in HSC increased mitochondrial biogenesis and elevated levels
of reactive oxygen species (ROS). Short-term rapamycin treatment greatly enhanced the efficacy of
influenza vaccination in aged mice.
Past services to SCBA
Attended SCBA meetings and gave talks in 1998, 2004 and 2009.
Selected Honors and Awards, and non-SCBA services
2006
American Cancer Society Research Scholar
2011 – 2013
CBIS, Secretary.
2014 – 2016
CBIS, Board member.
Candidates for the Council 4. COUNCILOR: (VOTE FOR 2) Keji Zhao (NHLBI, Nat. Institutes of Health) (Jan. 1, 2016 -­‐ Dec. 31, 2019) Mien-­‐Chie Hung (MD Anderson Cancer Center) _____ Yimin Zou (University of California, San Diego) _____ Min Han (Univ. of Colorado, Boulder) _____ _____ Keji Zhao, Ph.D.
Current Position:
Senior Investigator and Director
Systems Biology Center
National Heart, Lung and Blood Institute, NIH
Education and Training
Diploma, Changwei Normal College, China, 1980
M.Sc. in Organic Chemistry, Northeast Normal University, China, 1985
Ph.D. in Molecular Biology, University of Geneva, Switzerland, 1996
Postdoctoral Fellow, Stanford University, California, 1996-1999
Previous Positions:
1999 – 2006
2007 – 2011
2011 – present
Tenure-Track Investigator, Center of Immunology,
National Heart, Lung and Blood Institute, NIH, Bethesda, MD
Senor Investigator, Center of Immunology, NHLBI, NIH
Senior Investigator and Director, Systems Biology Center, NHLBI, NIH
Research Interest:
The research in my laboratory focuses on the epigenetic and epigenomic regulation of
cell differentiation and cell memory. My laboratory developed the ChIP-Seq and MNaseSeq techniques and also developed corresponding algorithms to analyze these data. We
applied these techniques to genome-wide mapping of histone modifications, nucleosome
occupancy, and binding profiles of histone modification enzymes and transcription
factors.
Past services to SCBA:
2011
President-elect, SCBA Washington DC-Baltimore Local Chapter
2012
President,
SCBA Washington DC-Baltimore Local Chapter
2011 to present Editorial Board of Cell & Bioscience
2009
Co-organizer of a session of 2009 SCBA Biannual Meeting
2013
member, meeting program committee of 2013 SCBA Biannual Meeting
2013 to 2015
member,
SCBA Membership Committee
Selected Honors and Awards:
2007
2007
2008
2008
2011
2012
National Institutes of Health Merit Award for “Innovative contributions that have
provided novel insights into epigenetic control of gene expression”
Appointed to the Senior Biomedical Research Service
APAO Award for Significant Accomplishments in Biomedical Research at NIH
National Institutes of Health Merit Award
NIH Director’s Award
Election to AAAS Fellows
Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
MIEN-CHIE HUNG
PROFESSOR AND CHAIR
eRA COMMONS USER NAME (credential, e.g., agency login)
[email protected]
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
NATIONAL TAIWAN UNIVERSITY, TAIWAN
NATIONAL TAIWAN UNIVERSITY, TAIWAN
BRANDEIS UNIVERSITY, MASSACHUSETTS
WHITEHEAD INSTITUTE, MIT, MASS.
B.S
M.S.
PH.D.
POSTDOC
07/73
07/77
05/83
08/86
CHEMISTRY
BIOCHEMISTRY
BIOCHEMISTRY
ONCOGENE
Personal Statement
I am a Principal Investigator for a P01, an R01, a Susan G. Komen grant, a
CPRIT and a co-Project Leader for the Ovarian Cancer SPORE. I also
serve as Program Leader of Cell Biology and Signal Transduction
Program, Core Director of ShRNA and ORFeome Core Facility and
Associate Director of Basic Science Programs of Cancer Center
Supporting Grant. Currently, my group’s research focuses on three
themes in cancer research: 1) discovery of novel functionality of
epidermal growth factor receptor (EGFR) family which might provide
useful insight to understand cancer formation and development, 2)
identification of crosstalks of signal pathways/networks in cancer cells
and tumor microenvironment which could potentially predict resistance
to target therapy, and 3) development of marker-guided targeted
therapy which will effectively treat cancer patients.
Positions and Honors
Professional Experience:
1986-1991 Assistant Professor, Department of Tumor Biology, The University of Texas M.D. Anderson
Cancer Center
09/91-08/94 Associate Professor, Department of Tumor Biology, The University of Texas MD Anderson
Cancer Center
09/94Professor, The University of Texas M.D. Anderson Cancer Center
5/99-02/00 Hubert L. and Olive Stringer Distinguished Professorship in Cancer Research, U.T. MD
Anderson Cancer Center
03/00-12/02 Ruth Legett Jones Chair, Department of Molecular and Cellular Oncology, U.T MD Anderson
Cancer Center
01/03Ruth Legett Jones Distinguished Chair
03/00Chair, Department of Molecular and Cellular Oncology, U. T. MD Anderson Cancer
Center
09/08Director, Center for Biological Pathways, U. T. MD Anderson Cancer Center
03/10Vice President for Basic Research, U.T. MD Anderson Cancer Center
07/13Associate Director, Basic Science Programs, CCSG, U.T. MD Anderson Cancer Center
0925-0001/0002 (Rev. 08/12)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Honors and Awards:
1989-90 John P. McGovern Outstanding Teacher Award U.T. H.S.C. -Houston (1992-93, 1998-99),
1993
Faculty Achievement Award in Education (1993) and in Basic Research (1998), UTMDACC
1996
Member, Pathology B Study Section (1996 – 2000) and Sub-committee C (2001-2005), NIH.
Editorial Board, Clinical Cancer Research (1999–), Cancer Cell (2001-) and Cancer Research (2002-).
2002
Academician of the Academia Sinica, Taiwan
2006
Member, The University of Texas Academy of Health Science Education.
2007
Distinguished Teaching Professor, The University of Texas M. D. Anderson Cancer Center.
2010-16 Full Member, Scientific Advisory Council, Susan G Komen.
2010
Fellow, section of Biological Sciences, American Association for the Advancement of
Science.
Selected Services/Activities to SCBA:
• Vice-President, Houston Chapter - Society of Chinese Bioscientists in America, 1988-1989.
• President, Houston Chapter - Society of Chinese Bioscientists in America, 1989-1990.
• Session Chairman, Houston Chapter, Third Annual Symposium, Houston, TX, 12/1989
• Session Co-Chairman Fourth International Symposium & Workshop, Singapore, Singapore, 6/1992
• Session Co-Chairman Fifth International Symposium & Workshop, Washington, DC, 6/1993
• Session Chair, Biotechnology Section, Galveston, TX , 4/1998
• Session Chair, Frontier of Biotechnology and Biomedical Science in the New Millennium, The 9th
SCBA International Symposium, Taipei, Taiwan, 8/6/2001
• President (international), 1/2004−12/2005
• Member, International Advisory Committee 10th SCBA International Symposium, Beijing, China,
6/2004
• Session Co-Chair, Session: Gene Therapy for cancer, The 10th SCBA International Symposium, Beijing,
China, 7/2004 & The 11th SCBA International Symposium, San Francisco, CA, 7/2006
• Co-Chair, The 11th SCBA International Symposium, San Francisco, CA, 7/2006
• Faculty Club, TX Chapter, “A Novel Pathway Linking Cancer, Obesity and Diabetes; and Development
of Targeted Cancer Gene Therapy”, Houston, TX, December 14, 2007.
• Achievement Award and the Acceptance Speech, "To believe or not to believe: Trafficking of
Membrane Tyrosine Kinase Receptors to the nucleus-mechanism, function and clinical implication",
2008 SCBA TX Chapter Symposium, Houston, TX, April 19, 2008.
• Co-Chair, Scientific Program Session Chair on Cancer Biology Workshop, 12th SCBA International
Symposium, Taipei, Taiwan, 6/2009
• Session Co-Chair, Session: Cancer Etiology: Inflammation, Virology, and Cancer; and Session: Cancer
Biomarkers and Experimental Therapeutics, 13th SCBA International Symposium, Guangzhou, China,
7/2011.
• SCBA Presidential Award, July 2011.
• Keynote Speaker, Cross talk signaling pathways to predict drug resistance: pave a way to develop
personalized cancer therapy, Biennial SCBA Texas Chapter China Symposium, Nanjing, China, 9/2012
• Session speaker and co-Chair, Session: New Frontier in Cancer Metastasis, Chair: Dihua Yu, 14th SCBA
Biennial Meeting, Xi’An, China, July 18-22, 2013.
• Member, Planning Committee, 2014 TX Chapter Annual Meeting
• Chair, Scientific Program, 2015 SCBA Biennial Symposium, Taipei, Taiwan, June 26-29, 2015
0925-0001/0002 (Rev. 08/12)
Page
Biographical Sketch Format Page
YIMIN ZOU, Ph. D.
Current Positions
Professor and Chair
Neurobiology Section
Biological Sciences Division
University of California, San Diego
Education and Training
B.S., Genetics, Fudan University, China
1988
Ph.D., Biochemistry and Molecular
Biology, University of California, San
Diego and Davis, 1995
Postdoctoral Fellow, Developmental
Neuroscience, University of California,
San Francisco, 2000
Previous Positions
2000-2006 Assistant Professor, Department of Neurobiology, the University of
Chicago
2006-2006 Associate Professor (with tenure), Department of Neurobiology, the
Univesity of Chicago
2006-2011 Associate Professor, Neurobiology Section, University of California,
San Diego
2011-present Professor, Neurobiology Section, University of California, San Diego
2012-2014 Vice Chair, Neurobiology Section, University of California, San Diego
2014-present Chair, Neurobiology Section, University of California, San Diego
Research Interest
My lab studies molecular and cellular mechanisms of axon guidance, synapse
formation, and assembly, stability and regeneration of neural circuits. We identify
molecular guidance cues that provide directional information for axon wiring in vivo
as well as signal transduction pathways and cell biological mechanisms underlying
growth cone turning. We also study synaptogenesis and how specific synaptic
connection patterns emerge from the interplay of molecular guidance system and
neural activity. We are interested in how central nervous system responds to
traumatic injury and develop therapeutic approaches to promote axonal and
neuronal survival to combat degenerative disorders and improve axon regeneration
and functional recovery following spinal cord injury.
Selected Honors and Awards, and non-SCBA Services
1989-1993
1993-1995
1995-1996
1996-1998
1999-2000
2002-2005
2002-2004
2003-2005
2003
2005
2006
2006
2008
2009
2011
2011
2012
2012
2013
2013-
2013
2013-2016
2014
2015
2016
2017
CUSBEA Fellowship
Institutional Predoctoral NRSA, NIH
Institutional Postdoctoral NRSA, NIH
Individual Postdoctoral NRSA, NIH
Postdoctoral Fellowship from the Spinal Cord Research Foundation
Schweppe Foundation Career Development Award
March of Dimes Basil O’Connor Starting Scholar Research Award
Alfred P. Sloan Research Fellow Award
W. M. Keck Foundation Research Achievement Award (Semi-finalist
in Keck Young Scholar Competition)
Chair of “Minisymposium on Wnt Signaling in Neural Circuit
Development” at Society for Neuroscience Meeting. Washington, DC.
Gail Beach Memorial Seminar Series at the University of Miami Miller
School of Medicine. Miami, Florida
Keynote Speaker at Midwest Student Biomedical Research Forum.
Omaha, Nebraska.
Chair of “Symposium on Genetic determinants specifying neuronal
connections” at Society for Neuroscience Meeting. Washington, DC.
Killam Research Seminar the Montreal Neurological Institute McGill
University. Montreal, Canada.
Chair of Symposium Organizer: Signaling and cell biological
mechanisms of growth cone guidance at 8th IBRO World Congress of
Neurosciences. Florence Italy
Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits.
Suzhou China
S. T. Huang-Chan Memorial Lecture Hong Kong University, Hong Kong,
China
北京生科院精品讲座
Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits.
Suzhou China
Member and Secretary of Board of Directors of Ray Wu Memorial
Fund and CBIS
Director’s Seminar Series (贝时璋讲座) Institute of Biophysics, CAS
Honorary Professor of the University of Hong Kong
Dean’s Seminar Series (院长讲座)Peking University Medical School
AbCam Meeting on Frontiers of Signaling. Shanghai, China.
Co-Organizer of Cold Spring Harbor Asia Meeting on Neural Circuits.
Suzhou China
Co-Organizer of Keystone Symposium on Neural Circuits, Colorado
MIN HAN, Ph.D.
Current Position:
Investigator of Howard Hughes Medical Institute
Professor, Dept of MCDB, Univ. of Colorado at Boulder
Member of Cancer Center, Univ. of Colorado at Denver
Adjunct Professor and co-director, IDM, Fudan Univ.
Education
B.S., Biochemistry, Peking (Beijing) University, 1982
Ph.D., Molecular Biology Institute, UCLA 1988
Postdoctoral fellow, Caltech, 1988-1991
Research Accomplishments and Interests
My lab has been dynamic in selecting and addressing
diverse biological problems, primarily using C. elegans
and mouse as model organisms. In the 1990s, we
employed several genetic suppressor screens to identify
>12 highly conserved regulators of the RTK/Ras/MPK signaling pathway. Our later analysis of
nuclear positioning in the worm defined the SUN and KASH nuclear-envelope protein families, as
well as the concept of SUN-KASH universal pairing, followed by the functional analyses of the
complex in mouse. We were the first to report GW182 as an essential competent of miRISCs and
pioneered the application of the miRISC-IP approach to systematically analyze miRNA-target
interaction networks under various physiological conditions. We also took systematic approaches to
tackle the problem of “genetic redundancy” that masked the roles of many regulators, including
tumor suppressors and miRNAs in development. In the last 10+ years, we turned our attention to
understanding the functional consequence of fatty acid/lipid variations. Our efforts led to the
discoveries of the striking impact of specific lipid metabolism events on several signaling pathways
that control animal development and behaviors.
Honors, Awards and Service to the Chinese Scientist Community
1988-91
Fellow of the Life Science Research Foundation
1991-1997
Lucille P. Markey Scholar in Biomedical Science
1992-1995
Basil O'Connor Scholar of March of Dimes Foundation
1993-1996
Searle Scholar
1997-current
Selected and then renewed as a HHMI Investigator.
2011
Elected as Fellow of AAAS.
2000-2005
Members of Board Director, Vice President, CBI Society.
1996, 2004
Served as session chairs/speakers at SCBA meetings.
2010-current
Ad hoc member of evaluation committees, China Academy of Science
2011-current
Biology and Medicine Panel of the Research Grants Council of Hong Kong
1
Candidates for the Nomination Committee 5. NOMINATION: (VOTE FOR 6) Paul J. Chiao (University of Texas, Houston) _____ (Jan. 1, 2016 -­‐ Dec. 31, 2017) Yingzi Yang (Harvard University) _____ Huilin Zhou (University of California, San Diego) _____ Qi-­‐Jing Li (Duke University) _____ Wanjun Chen (NIDCR, Nat. Institutes of Health) _____ Julian J.-­‐L. Chen (Arizona State University) _____ Xin Wei Wang (NCI, Nat. Institutes of Health) _____ PAUL J. CHIAO, Ph.D.
Current Positions:
Ashbel Smith Professor,
Department of Molecular and Cellular Oncology
The University of Texas M. D. Anderson Cancer Center
University of Texas, Graduate School of Biomedical Sciences
Education and Training:
B.S., The University of Iowa, Iowa City, Iowa, 1986
Ph.D., The University of Texas Graduate School of
Biomedical
Sciences Postdoctoral Fellow, The Salk Institute for
Biological Studies
Previous Positions:
1995-2001
Assistant Professor, the University of Texas M.D. Anderson Cancer Center and
the University of Texas Graduate School of Biomedical Sciences, Houston, TX
2001-2007
Associate Professor, the University of Texas M.D. Anderson Cancer Center and
the University of Texas Graduate School of Biomedical Sciences, Houston, TX
2007-present Professor, the University of Texas M.D. Anderson Cancer Center and the
University of Texas Graduate School of Biomedical Sciences, Houston, TX
22011-present Ashbell Smith Professor, the University of Texas M.D. Anderson Cancer Center
and the University of Texas Graduate School of Biomedical Sciences, Houston, TX
09/2011-2014 Co-Director, Cancer Biology Program, the University of Texas Graduate School
of Biomedical Sciences/ M.D. Anderson Cancer Center and the University of Texas Health
Science Center
Research Interest:
My laboratory has interests in regulation of gene expression and cell signaling in diseases. We first
identified constitutive activation of NF-κB in pancreatic cancer and revealed the mechanisms of
constitutive NF-κB activation, demonstrating NF-κB activation is required for mutant Kras to induce
pancreatic cancer. Subsequently, we identified the function of NF-κB constitutive activation in Sjögren's
Syndrome, common autoimmune disease. Our long term goal is not only to illuminate disease
mechanisms, but also identify innovative drug targets for improving current treatments.
Past services to SCBA
Served as Treasure, Secretary, President-elected, President (2014) of SCBA Texas Chapter.
Participated in organization of SCBA-Texas Chapter, The 27th, 28th, and 29th Annual Symposium
Selected Honors and Awards and non-SCBA Services:
1981 Undergraduate Scholarship, University of Iowa,
1988 American Legion Auxiliary Fellowship for Predoctoral Research Award, Univ. of Texas,
1991 National Institutes of Health Postdoctoral Fellowship.
2011 Ashbel Smith Professorship, the University of Texas M.D. Anderson Cancer Center
YINGZI YANG, PhD
Current Position:
Professor of Developmental Biology
Harvard School of Dental Medicine
Education and Training:
BS, Biophysics, Fudan University, China, 1988
PhD, Molecular Biology, Weill Medical College of Cornell
University and Sloan Kettering Cancer Institute, New York,
1996
Postdoctoral fellow, Harvard University, 1996-2000
Previous Positions:
2000- 2006
Investigator, National Human Genome Research Institute, NIH
2006- 2014
Senior Investigator, National Human Genome Research Institute, NIH
Research Interest:
My laboratory has a longstanding interest in understanding the functions and mechanisms of Wnt
and Hedgehog signaling in development and disease. My lab has made major contributions in
identifying the roles of Wnt and Hedgehog signaling in skeletal development and diseases. Our
research has successfully bridged discoveries of fundamental mechanisms with characterization
and treatment of diseases including severe birth defects, osteoporosis, osteoarthritis and heterotopic
bone formation. Our studies have revealed fundamental mechanisms of Wnt and Hedgehog signal
transduction and their critical roles in many aspects of embryonic morphogenesis and adult
physiology.
Awards and Honors
1995:
Vincent du Vigneaud Award of Excellence from the Weill Medical
College of Cornell University
1996-1999:
Postdoctoral fellowship award from the Cancer Research Fund
of the Damon Runyon-Walter Winchell Foundation.
2011:
SCBA Young Investigator Award
2011:
NIH APAO Outstanding Achievements and Merit Scholarship Award
2013:
Keynote speaker at the NIH ceremony of Asian-American month
Huilin Zhou, Ph.D.
Current Position:
Associate member, Ludwig Institute for Cancer Research
Professor, Department of Cellular and Molecular
Medicine, University of California, San Diego, CA
Education and training:
B.S. University of Science and Technology of China,
Hefei, P.R. China, 1991
Ph.D. Stanford University, Palo Alto, CA, 1998
Postdoc fellow, Institute for Systems Biology and
University of Washington, Seattle, WA, 2002
Research Interests:
Our research program focuses on understanding the regulatory mechanisms of genome maintenance
pathways including the DNA damage checkpoint and protein sumoylation. Genetic studies using the
yeast Saccharomyces cerevisiae as a model organism have established a key role of DNA damage
checkpoint kinases in suppressing gross chromosomal rearrangements (GCRs), a hallmark of human
cancers. We have developed quantitative phospho-proteomics to identify and characterize substrates
of DNA damage checkpoint kinases, as well as biochemical reconstitution of the activation of the
kinase cascade. More recently, we have discovered that SUMO E3 ligases have a major role in
suppressing duplication-mediated GCRs, which are driven by homeologous recombination, leading
to chromosomal translocation events. We have further developed a novel quantitative mass
spectrometry based assay to measure in vivo changes in protein sumoylation on a proteome-wide
scale. Application of this approach allowed us to obtain a comprehensive picture of the enzymesubstrate relationship in the SUMO pathways, including SUMO E3 ligases that catalyze the
attachment of SUMO to its substrates as well as SUMO isopeptidases that catalyze the removal of
SUMO. These studies have revealed that the SUMO pathway has a broad role in chromosome
biology, ranging from genome stability, gene silencing and chromosome segregation. We are further
extending our findings using yeast as a model system to human cells and study the conservation of
the underlying molecular mechanisms and their relevance to cancer etiology.
Selected honors and previous service to SCBA:
The NHGRI Genome Scholar Development and Faculty Transitional Award, 2002-2005.
Participants/speakers of past SCBA meetings.
QI-JING LI, Ph.D.
Current Positions:
Associate Professor of Immunology
Department of Immunology, Program of Molecular Cancer Biology, Duke
University Medical Center.
Education and Training:
B.S. in Biochemistry & Molecular Biology, Peking University, China, 1996
Ph.D. in Biochemistry & Molecular Biology, University of California, Riverside,
CA, 2002
Postdoctoral Research Associate, Howard Hughes Medical Institute, Stanford
University Medical School, CA, 2002-2008.
Previous Positions:
2008-2015 Assistant Professor, Department of Immunology, Program of
Molecular Cancer Biology, Duke University Medical Center.
Research Interest:
The major objective of my laboratory is to discover new immunoregulatory entities and to employ them to
modulate the strength and pattern of T cell responses for clinical intervention, especially, for cancer
immunotherapies. Currently, our major focus is microRNA (miRNA). Emerging evidence indicates that
miRNAs are indispensable controlling elements of the adaptive immune system and can be used as an effective
tool to manipulate a specific immune response. Despite challenges and complexities surrounding miRNA
research, the biochemical characteristics of miRNAs bring several unique opportunities to basic and clinical
medicine: I) In comparison to other forms of extracellular nucleic acids, miRNAs are exceptionally resistant to
RNase degradation in body fluids. Also, PCR and sequencing based technologies for nucleic acid detection are
far more sensitive and quantitative than those for protein detection. Therefore, circulating miRNAs represent a
novel class of non-invasive biomarkers for various disease diagnosis and prognosis such as cancer. II) Unlike
the lengthy and costly process of protein-based drug development, designing an oligonucleotide-based miRNA
mimetic or antisense-based miRNA inhibitor for immune modulation is straightforward. We are actively
pursuing novel immunoregulatory miRNAs for therapeutic targeting. III) Identifying miRNA targets is a way
to discover novel proteins, or novel functions of known proteins in T cell biology. In contrast to siRNA-based
methods that normally employ hundreds of thousands of hits, the limited number makes “reverse epigenetic
screening” of a miRNA expressing/targeting library much more feasible. In addition, complementary paring
between the miRNAs seed region and target mRNA sequence is required for most miRNAs to execute gene
regulation. Therefore, my laboratory employs miRNAs as tools for discovery.
Selected Honor and Awards and non-SCBA services:
2003-2006
2009-2012
2010-2012
2010-2014
201220122015-
Helen Hay Whitney Foundation Postdoctoral Research Fellowship
Whitehead Scholarship, The Whitehead Family Foundation
The American Diabetes Association Junior Faculty Award
The American Cancer Society Research Scholarship
External reviewer for Portuguese Foundation for Science and Technology (FCT)
Reviewer for the Cellular and Molecular Immunology-B study section, Center for Scientific Review,
NIH, USA.
Reviewer for the Immunology and Microbiology Panel, Human Exploration Research Opportunities,
National Aeronautics and Space Administration (NASA), USA.
WANJUN CHEN, M.D.
Current Positions:
Senior Investigator
Chief, Mucosal Immunology Section, OPCB, NIDCR, NIH
Education and Training:
M.D., Qingdao Medical College, China, 1984
M.S. Immunology, Shandong Medical University
Shandong Academy of Medical Sciences, China, 1987
Postdoctoral fellow, Harvard Medical School, MA, 1992-1996
Previous Positions:
1997-2003, Senior Staff Fellow, Cellular Immunology Section, OIIB, NIDCR,
NIH
2004-2010, Tenure-track Investigator, Chief, Mucosal Immunology Unit, OIIB, NIDCR, NIH
2011-present, Senior Investigator (tenured), Chief, Mucosal Immunology Section
OPCB, NIDCR, NIH
Research Interest:
My laboratory is elucidating mechanisms of TGF-β regulation of T-cell immunity and tolerance with focus on
regulatory T cells (Tregs), and manipulating T-cell immunity versus tolerance in animal models to
understand the pathogenesis of autoimmunity and inflammation, cancer and infectious diseases and to
develop potential therapies for relevant human diseases. We discovered TGF-β induces Foxp3 in naïve CD4+
T cells and converts them into Foxp3+ regulatory T cells.
Past and current services to SCBA:
Session Chair, 13rd International SCBA Conference, Guangzhou, China, 2011
Keynote Speaker, Annual Meeting of The Texas Chapter of SCBA, Houston, 2011
Chair, SCBA Joint Session, Chinese Biopharmaceutical Association USA (CBA) Annual Meeting,
Rockville, MD, 2014
Co-Chair, SCBA DC-Baltimore Chapter Annual Scientific Symposium, Baltimore, 2015
Session Co-Chair, The 15th International SCBA Symposium, Taipei, 2015
President, SCBA Washington DC-Baltimore Chapter, 2015
Selected Honors and Awards and non-SCBA services:
Invited Speaker, NIH Director’s Seminar Series, NIH, 2009
Co-organizer, Keystone Symposium, TGF-β in Immune Responses, Utah, 2011
The Wang Ying-Lai Memorial Lecture, Houston, 2011
Scientific Achievement Award, NIH Asian and Pacific Islander American Organization, NIH, 2013
Chair, NIH Stadtman Tenure-track Investigator Search Immunology Committee, NIH 2011-12
JULIAN J.-L. CHEN, Ph.D.
Current Position
Associate Professor
Department of Chemistry and Biochemistry
Arizona State University, Tempe
Education and Training
B.S., Biology, National Cheng-Kung University, Taiwan, 1991
Ph.D., MCDB, Indiana University, Bloomington, IN, 1997
Postdoctoral Fellow, Johns Hopkins University School of Medicine, 1998-2004
Previous Positions
1991 –1992 Research Technician
Institute of Molecular Biology, Academia Sinica, Taiwan
2003 –2004 Research Associate
Department of Molecular Biology and Genetics
Johns Hopkins University, School of Medicine
2004 –2010 Assistant Professor
Department of Chemistry & Biochemistry
Arizona State University, Tempe, Arizona
2004 –2010 Assistant Professor (Joint Appointment)
School of Life Sciences, Cellular & Molecular Biosciences Division
Arizona State University, Tempe, Arizona
Research Interest
Telomerase is a highly specialized reverse transcriptase that adds simple DNA repeats onto linear chromosome ends
to maintain genomic integrity and sustain cellular immortality in eukaryotes. My research aims to understand the inner
workings of telomerase and to develop telomerase-targeting therapeutics for aging, cancer and telomere-mediated
diseases. My research employs interdisciplinary approaches spanning biochemistry, bioinformatics, structural biology and
molecular genetics.
Honors and Awards
2000-2003 Fellow of The Leukemia & Lymphoma Society
2005
MARC Travel Award
2007-2012 NSF Faculty Early Career Development (CAREER) Award
Professional Service
Panel Reviewer for Grant Funding Agency:
NIH Study Section-Molecular Genetic - MGA (Regular Member, 2012-present)
Ad hoc Reviewer for Grant Funding Agencies:
National Institutes of Health (NIH) Study Section MGA (2011), National Science Foundation (NSF) (2006, 2010, 2012),
Maryland Technology Development Corporation (TEDCO) (2011), Austrian Science Fund (FWF) (2010), US-Israel
Binational Science Foundation (2006)
Editorial Board Member of Scientific Journals:
Journal of Biological Chemistry (2013 - present), Frontiers in Genetics – Non-coding RNA (2010 - present)
Meeting Session Chair:
The 2013 Telomeres and Telomerase Meeting at Cold Spring Harbor Laboratory, NY
Selected Publications
Qi, X., D.R. Rand, J.D. Podlevsky, Y. Li, A. Mosig, P.F. Stadler and J.J.-L. Chen (2015) Prevalent and distinct
spliceosomal 3ʹ′-end processing mechanisms for fungal telomerase RNA. Nature Communications 6, 6105.
Brown, A.F., J.D. Podlevsky, X. Qi, Y. Chen, M. Xie and J.J.-L. Chen (2014) A self-regulating template in human
telomerase. Proc. Natl. Acad. Sci. U.S.A. 111(31): 11311-11316. [From the Cover]
Huang, J., A.F. Brown, J. Wu, J. Xue, C.J. Bley, D.P. Rand, L. Wu, R. Zhang, J.J.-L. Chen* and M. Lei* (2014) Structural
basis for protein-RNA recognition in telomerase. Nature Structural and Molecular Biology 21: 507-512.
Qi, X., M. Xie, A.F. Brown, C.J. Bley, J.D. Podlevsky and J.J.-L. Chen (2012) RNA/DNA hybrid binding affinity determines
telomerase template translocation efficiency. EMBO J. 31: 150-161.
Bley, C.J., X. Qi, D.P. Rand, C.R. Borges, R.W. Nelson and J.J.-L. Chen (2011) RNA-protein binding interface in the
telomerase ribonucleoprotein. Proc. Natl. Acad. Sci. U.S.A. 108(51): 20333-20338.
Xin Wei Wang, Ph.D.
Current Positions:
Senior Investigator and Deputy Chief,
Laboratory of Human Carcinogenesis,
Center for Cancer Research, National
Cancer Institute
Education and Training:
B.S., Shanghai First Medical College, Shanghai, China, 1982
M.S., Chinese Academy of Sciences, Shanghai, China, 1984
Ph.D., New York University, New York, New York, 1991
Postdoc Fellowship, Roche Institute of Molecular Biology, Nutley, New Jersey, 1992
Previous Positions:
Senior Staff, National Cancer Institute, 1995-97
Chief, Liver Carcinogenesis Unit, National Cancer Institute, 1998-2005
Adjunct Associate Professor, University of Maryland Cancer Center, 2002Chief, Liver Carcinogenesis Section, National Cancer Institute, 2005Research Interests:
Want’s lab is interested in studying biochemical pathways related to human cancer with a special
focus on cancer functional genomics. Primary liver cancer is the second most deadly cancer in
men and fifth most prevalent cancer worldwide. It remains as the most difficult-to-treat
malignancies, with a 5-year survival rate lingering at 15% in the United States. His lab is
exploring molecular mechanisms to explain how cancer cells initiate and metastasize, and to
develop clinically relevant biomarkers and molecular genetic-based therapeutics for liver cancer.
Currently, his lab is centered on two main complementary research projects with an objective to
change the current status quo. Project one is to dissect molecular heterogeneity of liver cancer to
improve outcome among diverse populations. Project two is to apply integrated genomics to
identify drivers of human liver cancers.
Previous Services to SCBA:
SCBA life-time member since 2002
SCBA Baltimore-DC Chapter Treasurer since 2009
Selected Honors and Awards, and Services:
Federal Technology Transfer Awards (1998-2012)
Board of Directors, International Society of Gastroenterological Carcinogenesis, 2003-09
Natural Sciences Award (first place), The Ministry of Education of China, 2008
NCI Outstanding Mentor Award (Mentor of Merit), 2009
NIH APAO Outstanding Scientific Achievement Award, 2010
The SCBA Outstanding Leadership and Service Award, 2011
NIH Director’s Award, 2013, NIH Merit Award, 2009, 2013
Governing Board, International Liver Cancer Association, 2013Blue Faery Award for Excellence in Liver Cancer Research, 2014
Candidates for the Membership Committee 6. MEMBERSHIP: (VOTE FOR 6) Yi Li (Baylor College of Medicine) _____ (Jan. 1, 2016 -­‐ Dec. 31, 2017) Xuhang Li (Johns Hopkins University) _____ Wei Gu (Columbia University) _____ Zhibin Chen (University of Miami) _____ Yingming Zhao (University of Chicago) _____ Deyu Fang (Northwestern University) _____ Yixian Zheng (Carnegie Institution of Science) _____ Yue Xiong (University of North Carolina) _____ YI LI, Ph.D.
Current Position:
Associate Professor, Lester & Sue Smith Breast Center and
Department of Molecular and Cellular Biology, Baylor College of
Medicine
Education and Training:
B.S., Yangzhou University, 1984
M.S, Yangzhou University, 1987
Ph.D. Michigan State University, 1996
Postdoctoral Fellow, Michigan State University, 1996-1997; NCI, 19972000; MSKCC, 2000-2002
Previous Positions:
12/2002 – 3/2011 Assistant Professor, Breast Center and Department
of Molecular and Cellular Biology, Baylor College of
Medicine, Houston, TX.
5/2005 – present Associate Member, Stem Cells and Regenerative Medicine, Baylor College of
Medicine.
12/2011 – present Adjunct Professor, The University of Texas Health Science Center at Houston
5/2011 – present Faculty Associate, Huffington Center on Aging, Baylor College of Medicine.
4/2011 – present Associate Professor, Breast Center and Department of Molecular and Cellular
Biology, Baylor College of Medicine, Houston, TX.
Research Interest:
The Li laboratory studies the molecular and cellular mechanisms of breast cancer initiation and
evolution and translates this knowledge into breast cancer prevention and treatment in both preclinical
models and a clinical setting. The Li laboratory pioneered the use of the RCAS-TVA avian retroviral
system for closely mimicking human breast cancer initiation in mice. The Li laboratory use this method
and genetically engineered mouse models as well as human cell lines and patient tissues to study the
fundamental questions in breast cancer initiation, progression, and metastasis as well as prevention.
The Li laboratory also studies how pregnancy, diabetes, and antipsychotic drugs impact breast cancer
risk as well as breast cancer stem cells. The main signaling pathways that are studied in the Li
laboratory include Wnt, LGR4, ErbB2, and JAK2-STAT5.
Previous Service to SCBA:
2008-2009
Treasurer, SCBA-Texas Chapter,
2011-2012
President-Elect, SCBA-Texas Chapter,
2012-2013
President, SCBA-Texas Chapter,
2013
Chair, Annual symposium of SCBA-TX
2013
Co-Chair, The Second Biennial International Symposium of SCBA-TX: Jiangsu
Biomedical Symposium on Cancers and Other Human Diseases: From Mechanisms to
Bedside. Nanjing, China. 2012
2013-2015
Member of the SCBA membership committee
XUHANG LI, PhD
Current Position:
Assistant professor of medicine
Department of Medicine, GI Division
Johns Hopkins University School of Medicine
Education and Training:
Bachelor of Science: Department of Biology, Shandong University, China, 1983,
Master of Science:
Institute of Botany, Chinese Academy of Science, Beijing,
China, 1988,
Ph.D.:
Department of Cell Biology and Molecular Genetics,
University of Maryland College Park, Maryland, 1998,
Post-doctoral fellow: Laboratory of Molecular Biology, National Cancer Institute, National Institute of Health,
Bethesda, Maryland, 1998
Department of Medicine, Johns Hopkins University School of Medicine, 1999-2004
Previous Positions
1988-1990
Faculty research associate, Institute of Botany, Chinese Academy of Science, Beijing China
1990-1992
Research associate, University of Maryland, College Park, Maryland
2002
Instructor, John Hopkins University, School of Medicine, Baltimore, Maryland
2006
Assistant professor, John Hopkins University, School of Medicine, Baltimore, Maryland
RESEARCH ACTIVITIES
My laboratory in the GI Division/Department of Medicine conducts vigorous research in two major areas of GI
diseases: inflammatory bowel disease (IBD) and diarrhea. We have extensive expertise and experience in
protein biochemistry and proteomics, as well as in applying various biochemical, molecular and proteomic
approaches in studying IBD and diarrhea associated with disregulation of intestinal transporters. Specifically,
our research projects include: 1). Biomarker Discovery and Development for Diagnosis and Prognosis of
Inflammatory Bowel Disease (IBD) and Other Autoimmune Diseases. Through various state-of-art
technologies, including high-throughput protein chip technology and multiplex ELISA, we have recently
identified multiple interesting and potentially high-value protein/antibody candidates that may be developed as
diagnostic and or prognostic biomarkers for IBD. Biomarker of other autoimmune disorders, such as
autoimmune liver diseases as well common GI disorders such as irritable bowel syndrome (IBS) are also under
our investigation. 2). Exploring Molecular Pathogenesis and Developing Novel Therapeutics of Inflammatory
Bowel Disease (IBD). Using various biochemical and molecular technologies, including quantitative
proteomics, flow cytometry, gene-profiling, we are identifying novel signaling pathways that are potentially
involved in pathogenesis of IBD or diarrhea. Research involves both human and multiple animal models of
IBD. Our lab maintains more than eight different specific gene-knockout mouse lines that are used as model
systems for molecular dissecting pathogenic mechanisms and developing new therapeutic of IBD.
Past service to SCBA:
- Live-time membership
- Organizing happy hours, dinner and picnic, together with Dr. Aiping Zhao for SCBA activity and membership
drives
Honors and Awards
1997
Elected to the Honor Society of PHI KAPPA PHI
1997
Graduate School Goldhaber Award, University of Maryland at College Park
2002-2007
The NIH Research Scientist Career Development Award
2005
Scientist of the Year Award, Department of Medicine/GI Division, Johns Hopkins university
School of Medicine
2007Visiting Research Professorship, Shanghai Jiaotong University School of Medicine
2012Visiting professorship, Wuhan University and PLA Military Hospital of Beijing
Wei Gu, Ph.D.
Current Positions:
Abraham and Mildred Goldstein Professor endowed chair Professor
and Vice-Chairman for Cancer Research at the department of
Pathology and Cell biology and Institute for Cancer genetics in
Columbia University, New York, NY, USA.
Education and Training:
B.S. Peking University, Beijing, China, 1986
Ph.D. Columbia University, New York, USA, 1995
Postdoctoral Fellow, Rockefeller University, New York, 1995-1998
Previous Positions:
1999 -2004
Assistant Professor (Tenure-track), Columbia
University Medical Center, New York, NY
1999 -Present Principal Investigator/Member, Columbia University Herbert Irvine Cancer
Center
2004 -2006
Associate Professor (Tenured)
2007-Present
Full Professor at Columbia University Medical Center
2013-Present
Abraham and Mildred Goldstein Endowed Chair, Columbia University
2013-Present
Vice-Chairman for Cancer Research at the department of
Pathology and Cell Biology, Columbia University, New York, USA
Research Interests:
My laboratory is recognized for the pioneering contributions to p53 modifications in tumor
suppression. First, we discovered that p53 activity is controlled in large part by acetylation and
deacetylation. My lab has established that acetylation of specific p53 residues is required for its
transcriptional function and acts as the primary signal to differentially induce its canonical
functions in apoptosis, cell growth arrest and senescence. Second, my lab has identified
“dynamic ubiquitination” (polyubiquitination, monoubiquitination and deubiquitination) as the
major mechanism by which the stability and subcellular localization of p53 protein are
determined. Notably, several of our findings have had important implications well beyond p53
biology. For example, the studies of p53 acetylation laid the foundation for the current view that
reversible acetylation is a general mechanism for regulation of non-histone proteins. Overall, my
laboratory plays a leading role in the field of mechanistic studies of p53-mediated tumor
suppression and our studies have uncovered several new strategies to target the tumor
suppression pathway therapeutically.
Past services to SCBA
Session Chair, Scientific Program Committee, 11th SCBA International Symposium. 2006
Selected Honors and Awards
1995
Columbia University Dean’s Award for Outstanding Research Achievement.
1995-1998 Life Science Research Foundation Fellowship for Advanced Cancer Studies.
1999-2000 America Cancer Society Award
2000-2002 Avon Scholar Award
2001-2005 Irma T. Hirschl Trust Award
2001-2006 Leukemia & Lymphoma Society Scholar
2006
The Stohlman Scholar
2007-2011 Ellison Medical Foundation Senior Scholar in Aging
ZHIBIN CHEN, M.D., Ph.D.
Current Positions:
Associate Professor, Department of Microbiology and Immunology,
Miller School of Medicine
Member, Sylvester Comprehensive Cancer Center
University of Miami, Miami, FL
Education and Training:
M.D., Luzhou Medical College, China, 1988
M.S., Immunology, Tianjin Medical College, China, 1991.
Ph.D., Immunology, Duke University, NC, 2000.
Postdoctoral fellow. Harvard Medical School, MA, 2001-2006
Previous Positions:
1991-1994
Assistant Investigator, Chengdu Institute of Biological Products, Ministry of Public Health,
Chengdu, Sichuan, China
2001-2006
Research Fellow, Joslin Diabetes Center, Harvard Medical School, Boston, MA
2007-2013
Assistant Professor, Department of Microbiology and Immunology, University of Miami Miller
School of Medicine, Miami, FL
2007-present Affiliated Member, Diabetes Research Institute, University of Miami Miller School of Medicine,
Miami, FL
2009-present Member, the Sylvester Comprehensive Cancer Center, University of Miami Miller School of
Medicine, Miami, FL
Research Interest:
My search program mainly focuses on immune tolerance mechanisms, using murine models of human diseases, in
synergy with clinical studies. My group discovered bystander tissue cell growth as a mechanism of tissue regeneration at
the front of immune damage. We also tackle on a basic puzzle in immunology, how the clonal selection theory fits at the
intestinal interface where “friendly” bacteria largely outnumber the eukaryotic cells of a mammalian body. We discovered
cross-differentiation from CD8 lineage to MHC class-I-restricted CD4+Foxp3+ regulatory T cells and found evidence for
a “selfless” mode of immune tolerance induction.
Selected Honors and Awards, and non-SCBA services:
1999-present Regular Member, American Association of Immunologists
2001
Postdoctoral Fellowship, Juvenile Diabetes Research Foundation International.
2004
NRSA Fellow, Postdoctoral Training Program in AIDS Research (DFCI/NIH)
2014
NIDDK/NIH Review Committee. ZDK1 GRB-S (O4). Consortium on Beta-cell Death and
Survival (HIRN-CDBS) (UC4).
2015
NIDDK/NIH Review Committee. GRB-J M6. Collaborative Interdisciplinary Team Science in
NIDDK Research Areas (R24).
2015
NIDDK/NIH Review Committee. Consortium on Beta-cell Death and Survival (HIRN-CBDS)
(UC4) (HIRN-CTAR) (UC4).
Yingming Zhao, Ph.D.
Current Position:
Professor, Ben May Department for Cancer Research
The University of Chicago
Education:
B.S., East China University of Science and Technology,
Shanghai, China, 1984
Ph.D., The Rockefeller University, 1997
Previous Positions:
1998-2000
Assistant professor, Department of Human
Genetics, Mount Sinai School of Medicine
2000-2005
Assistant Professor, Department of
Biochemistry, UT Southwestern Medical Center
2005-2008
Associate Professor, Department of Biochemistry, UT Southwestern Medical
Center
2008-2011
Associate Professor, Ben May Department for Cancer Research, The University
of Chicago
2011-present Professor, Ben May Department for Cancer Research, The University of Chicago
Research Interest:
The Zhao Lab’s main research interests lie in developing and applying MS-based
proteomics technologies to discovery of cellular pathways. He also use an integrated
approach, involving proteomics, biochemistry, molecular biology, and cell biology to
decode protein post-translational modification (PTM) networks that have implications for
human health and are not amenable to conventional techniques. His lab recently
discovered seven types of new lysine acylation pathways: propionylation, butyrylation,
crotonylation, malonylation, succinylation, glutarylation, and 2-hydroxyisobutyrylation.
They identified more than 200 new histone marks, which doubles the tally of the
previous known histone marks discovered during the first forty years of chromatin
biology. They revealed numerous enzymes for the new PTM pathways. Specifically, his
lab is the first who demonstrates acetylation-independent functions of deacetylases,
including Sirt5 as a desuccinylase, demalonylase, and deglutarylase. His laboratory
demonstrates that the new PTM pathways have critical roles in epigenetic regulation
and cellular metabolism. And these pathways can explain cellular dysfunctions
associated with diverse inborn metabolic diseases, therefore offering new avenues for
therapeutic intervention.
Deyu Fang, Ph.D.
Current Positions:
Associate Professor
Department of Pathology,
Northwestern University Feinberg School of
Medicine,
Education and training:
B.S. Weifang Medical College, China, 1991
M.S. Dalian Medical University, China, 1994
Ph.D. Gunma University School of Medicine,
Japan, 2000.
Postdoctoral fellow, La Jolla Institute for Allergy and Immunology, San Diego, CA, 2003
Previous Positions:
2003-2005, Instructor (Research Investigator), Department of Biochemistry,
University of Michigan School of Medicine.
2005-2009, Assistant Professor, Department of Microbiology and Immunology
University Of Missouri School of Medicine
2009-present, Associate Professor, Department of Pathology
Northwestern University Feinberg School of Medicine
Research Interests:
My laboratory is interested in understanding the molecular mechanisms in immune regulation and
autoimmune diseases in mouse and human. In particular we are focusing on studying the posttranslational protein modifications, including ubiquitination and acetylation in regulating the
development, activation and differentiation of immune cells during infection and inflammatory
response.
Yixian Zheng, Ph.D.
Current Position:
 Investigator, Dept. of Embryology, Carnegie
Institution for Science, Baltimore, MD
 Adjunct Professor, Dept. of Biology, Johns
Hopkins University (JHU)
Education and Training
09/1980 – 07/1984
B.S. in Genetics, Sichuan University, Sichuan, China
01/1987 – 09/1992
Ph.D, Ohio State University, Columbus, Ohio
10/1992 – 08/1996
Postdoctoral Fellow, University of California, San Francisco
Previous Positions:
09/1984 – 11/1986
Lecturer, Southwestern Agricultural University, Sichuan, China
09/1996 – Present
Investigator, Department of Embryology
Carnegie Institution for Science, Baltimore, MD
1996 – 2007
Adjunct Assistant, Associate Professor, Professor
Dept. of Biology, JHU
2000 – 2012
HHMI Investigator, Howard Hughes Medical Institute
Research Interest:
My lab has a long-standing interest in cell division. In recent years, the findings we have made
have broadened our research scope to include the study of stem cells, genome organization,
and lineage specification using animal models. We have three research areas. 1. The
mechanism of cell division. 2. The mechanism of genome organization in development,
homeostasis, and aging. 3. The influence of cell morphogenesis on cell fate decisions. We use
a wide range of tools and systems, including genetics in model organisms, cell culture,
biochemistry, proteomics, genomics in our research.
Services to SCBA:
Chair and organizer: the First Baltimore-DC local chapter symposium, Baltimore, MA
Selected Honors and Awards:
1997 – 2001: PEW Scholar Award (Awarded by PEW Charitable Trusts)
1999: Women in Cell Biology Award (Junior) (American Society for Cell Biology)
07/2007: Keynote Speaker, Gordon Conference - Motile & Contractile Systems
09/2008: National Associate of the National Research Council, the National Academies of
Sciences
08/2012 – 08/2016: Senior Scholar in Aging, Ellison Medical Foundation
1
Yue Xiong, Ph.D.
Current positions:
William R. Kenan Jr. Professor of Biochemistry and Biophysics
Leader, Cancer Cell Biology Program, Lineberger Cancer Center
University of North Carolina at Chapel Hill
Education and training
B.S., Biology, Fudan University, Shanghai, China, 1982
Ph.D. Molecular Biology, University of Rochester, 1989
Postdoctoral: Cold Spring Harbor Laboratory, 1990 - 1993
Previous positions
1993 – 1999: Assistant Professor
1999 – 2003: Associate Professor (tenured)
2003 – 2005: Professor
1993 –present: member, Lineberger Comprehensive Cancer Center
1993 – present: member, Program in Molecular Biology & Biotechnology
University of North Carolina at Chapel Hill
Research interests
I have long-standing interest in understanding the mechanisms of cancer development
and have been focusing on three areas. (1) The function and regulation of CDK inhibitor
genes. (2) The cell cycle control and p53 signaling by the ubiquitin pathway. (3) Cancer
metabolism.
Selected honors and awards
1995
1995
1999
1999
1999
2006
2011
2012
ACS Junior Faculty Research Award
Pew Scholar in Biomedical Sciences
AACR-G. Elion Cancer Research Award
Department of Defense Breast Cancer Research Career Development Award
UNC Hettleman Award for Scholarly Achievement
American Lung Association Diane Emdin Sachs Lung Cancer Award
UNC Battle Distinguished Cancer Research Award
Elected fellow, American Association for the Advancement of Science
Participation in SCBA
Life-time member since 1995
Speakers and session chairs at multiple SCBA meetings
1